HSF1経路を標的とする小分子:化学的戦略と治療的可能性
Caiyiren Wen1,2, Yiqi Geng1,2, Jiayue Pei1,2
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Journal of medicinal chemistry
|September 3, 2025
まとめ
熱ショック因子1 (HSF1) は細胞ストレスと癌の重要な調節因子ですが,従来では薬効性はありません. 最近の医薬品化学の進歩は,治療開発のためにHSF1を標的とする新しい小分子戦略を提供します.
科学分野:
- 生物化学
- 分子生物学
- 薬剤化学
背景:
- 熱ショック因子1 (HSF1) は細胞のストレス反応と癌の進行に不可欠です.
- HSF1の構造の乱れと結合ポケットの欠如は 治療対象として難しいものです
- 既存の研究は,がん,神経変性,代謝疾患を含む様々な病理におけるHSF1の役割を強調しています.
研究 の 目的:
- 熱ショック因子1 (HSF1) の活性を調節するための医薬品化学の最近の進歩をレビューする.
- 以前は薬効性のないHSF1を標的とした革新的な化学戦略の洞察を提供するためです.
- 腫瘍学,神経変性,代謝障害におけるHSF1阻害剤の治療の可能性を探求する.
主な方法:
- 最近の医学化学の文献と薬剤発見アプローチのレビュー.
- HSF1の機能領域と規制ネットワークを標的とした小分子調節器の分析.
- HSF1に固有の薬効性の課題を克服するための化学戦略の探索
主要な成果:
- 革新的な化学戦略を用いて,HSF1の様々な小分子調節剤が開発されています.
- 新しいアプローチは,直接の関与または間接的なネットワーク変調によるHSF1活動の規制を可能にします.
- HSF1調節のための化学空間は大幅に拡大しました.
結論:
- 最近の医学化学の進歩は"薬剤耐性"のタンパク質であるHSF1を標的とした実用的な戦略を提供している.
- これらの発見は,新しいHSF1阻害剤の設計のための基礎を提供します.
- HSF1の調節は,癌,神経変性疾患,代謝疾患の治療に有望である.
関連する概念動画
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:26Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K